SUNSHINE and SUNRISE Trials in HS
An expert in dermatology reviews the phase 3 SUNSHINE and SUNRISE trials evaluating the use of secukinumab given in 2-week intervals in patients with HS and shares clinical pearls for managing the condition.
Source: hcplive.com